drugset / Trial / NCT02003092
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.
Timeline
- Start
- 2013-08
- Primary completion
- 2019-10
- Completion
- 2019-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SUPINOXIN | Small molecule | — | Oral |